Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822583 · ClinicalTrials.gov registry record · Phase 4
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 285
- Enrollment target
NCT05822583 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 285 participants.
The verdict
NCT05822583, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 285 participants
- Enrollment target
Study Summary
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.
Interventions
- DRUG Placebo group
- DRUG abatacept infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2025-08-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05822583
The ClinicalTrials.gov registry entry for NCT05822583 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo group is the first listed.
NCT05822583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05822583 about?
NCT05822583 is a clinical study titled "Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial". COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low fl...
What is the current status of trial NCT05822583?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 285 participants. The study started on 2023-07-06. Estimated completion is 2025-08-11.
What interventions are being tested in trial NCT05822583?
The interventions under investigation include: Placebo group (DRUG), abatacept infusion (DRUG).
Who is sponsoring clinical trial NCT05822583?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.